CUA: Testosterone level should guide androgen deprivation therapyAnalysis shows importance of reaching low values CUA: Prostate inflammation cuts cancer riskFinding has implications for biopsy followup CUA: A new way to zap the prostate—MRI-guided laser ablation Outpatient procedure has low morbidity but high failure rate CUA: Survey reveals gaps in genitourinary cancer survivorship care Xtandi: new oral androgen receptor inhibitor for metastatic prostate cancer Drug is intended for patients who have undergone medical or surgical castration and who have received docetaxel therapy. Prostate cancer: More men can opt for active surveillance All conventional criteria need not be fulfilled, analysis shows U.S. guideline nixes prostate screening in under-55s Late toxicities of cancer drugs Cardiac, pulmonary, sexual, and neurologic toxicities that develop or persist after completing cancer drug therapy Prostate cancer: More men can opt for active surveillance Not all conventional criteria need to be fulfilled, analysis shows New U.S. guideline nixes prostate cancer screening in under-55s Two-year interval suggested for older men who opt for testing First Previous 36 37 38 39 40 Next Last